Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, beating analyst estimates of $3.19 billion and marking 12.5% year-on-year growth. Adjusted operating income reached $1.42 billion versus estimates of $1.37 billion, representing a 42.7% margin and a 3.9% beat, while adjusted earnings per share of $4.73 were in line with expectations. The company slightly raised its full-year revenue guidance to a midpoint of $13.15 billion, exceeding analyst forecasts by 0.7%. Operating margin declined to 37.4% from 38.8% in the same quarter last year.
Vertex Pharmaceuticals IncQ2 revenue beat and raised full-year guidance